GV20 Therapeutics to Present GV20-0251 Data at ESMO 2024

CAMBRIDGE, Mass., Aug. 21, 2024 -- GV20 Therapeutics, a clinical-stage company specializing in AI and genomics-based biotherapeutics, has announced that Dr. Kristopher Wentzel from The Angeles Clinic and Research Institute will present clinical data on the monotherapy dose escalation of GV20-0251 at the ESMO Congress 2024. This event will be held in Barcelona from September 13 to 17, 2024. GV20-0251 is noted as the first clinical-stage antibody therapeutic designed using AI to target an AI-predicted site.

The dose escalation study began on March 27, 2023, and has since enrolled patients across six different dose cohorts and two schedules. GV20-0251 has demonstrated a good safety profile and promising clinical efficacy as a monotherapy.

The oral presentation will take place during a mini oral session titled "Investigational Immunotherapy." The session is scheduled for Monday, September 16, 2024, from 10:15 to 11:45 AM in the Granada Auditorium - Hall 6. The presentation number is 1000MO, and the title of the presentation is "A phase 1/2, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors."

GV20 Therapeutics is developing a unique pipeline of next-generation biotherapeutics that combine the power of AI, genomics, and disease biology. Their leading program, GV20-0251, is a first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody. It targets the novel immune checkpoint IGSF8 to activate both innate and adaptive immune responses. This program is currently in a multi-center Phase 1/2 clinical trial involving patients with advanced solid tumors (NCT05669430). Beyond GV20-0251, the company's discovery pipeline includes both best-in-class and first-in-class antibody-drug conjugates (ADCs) and degraders.

GV20 Therapeutics is headquartered in Cambridge, Massachusetts.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!